Compare Ginkgo Bioworks Holdings Inc (DNA) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Wipro Limited — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.57 (market cap $772.39M), while Wipro Limited trades at $1.69 (market cap $16.36B). The key difference: Wipro Limited is far larger — about 21.2× Ginkgo Bioworks Holdings Inc's market cap, and Wipro Limited pays a 5.19% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Wipro Limited for 41 Days on average.
| DNA | WIT | |
|---|---|---|
Market Cap | $772.39M | $16.36B |
Volume | 6,453,273 | 6,583,554 |
Sector | Health | Technology |
52-Week High | $15.83 | $3.06 |
52-Week Low | $5.48 | $1.61 |
Typical Hold Time | 7 Days | 41 Days |
Enterprise Value | $874.34M | $14.47B |
Dividend Yield | — | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
Wipro (WIT) trades at $1.67, down 0.6% with bearish technical signals despite recent AI productivity gains. The company reported $890.88B revenue for 2025 with solid 13.92% net margins and reasonable valuation (P/E 12.78). Recent quarters show earnings misses, but cash flow remains strong at $25.02B. Analyst sentiment is mixed with only 19% buy ratings.
Wipro faces execution risks amid competitive IT services market, though AI initiatives show promise. The stock offers value pricing but requires earnings acceleration to justify higher multiples. Near-term performance depends on client spending recovery and AI deployment success.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
